Milrinone Injection

Function:
Milrinone is a cardiac drug formulated as an injection for the short-term intravenous treatment of patients with acute decompensated heart failure. It is suitable for the short-term treatment of severe heart failure that is refractory to other anti-heart failure drugs and acute heart failure after cardiac surgery.

Dosage:
Start giving a loading dose of 50 μg/kg, dilute the drug to 10-21 ml, and inject it slowly intravenously within 10 minutes. Then maintain the infusion, the dosage is 0.375-0.75μg/kg, and the total dosage per person should not exceed 1.13mg/kg. Patients with renal insufficiency should reduce the dose.

Adverse reactions:
Ventricular arrhythmias, hypotension, angina, chest pain, and headache are common. Hypokalemia, tremor, and thrombocytopenia are rare. Post-marketing adverse reactions reported include bronchospasm, anaphylactic shock, liver function abnormalities, skin allergic reactions and infusion reactions.

Drug contraindications:
Contraindicated during pregnancy and lactation if allergic to this product